Quest Diagnostics Incorporated ( DGX ) Q3 2014 Results - Earnings Call Webcast
Quest operating income off 63%
Quest Diagnostics (NYSE: DGX ) will report Q3 results on October 23 before the open. The conference call will begin at 8:30 am ET. Consensus view is EPS of $1.08 on revenues of $1.9B. Post your comment!
Quest Diagnostics released second-quarter performance ..... organic volume growth remains lackluster at Quest . On one hand, quarterly organic volume ..... quarters of declines. On the other hand, Quest continues to trail its main rival LabCorp
are reimbursed under Medicare and Medicaid respectively. In the U.S., Sonic remains a minnow compared with Quest Diagnostics and LabCorp, with a market share of about 1.5% versus 15%. The U.S. market remains attractive given expected
was with Oakmark Equity & Income's elimination of Quest Diagnostics DGX "> DGX . Clyde McGregor noted the following in his ..... and three that didn’t (Encana, Hospira and Quest Diagnostics )... In the case of Encana and Quest Diagnostics
molecular pathology codes and sequestration. As with Quest Diagnostics , we anticipate the pressure should lift somewhat now ..... believe this sets LabCorp apart from its largest rival Quest . LabCorp is on the cusp of rolling out its Beacon LBS
Quest Diagnostics posted tepid first-quarter performance ..... the quarter to change our thinking on Quest 's narrow economic moat. Although the ..... these slightly more positive trends, Quest 's operating margin fell yet again
t (Encana, Hospira and Quest Diagnostics ). Cimarex and Concho are oil and gas ..... position. In the case of Encana and Quest Diagnostics , fundamental underperformance ..... redeploy the money elsewhere. With Quest , its weakening market share and tougher
revealed in the remaining patent infringement cases it is involved in. These include lawsuits with Ambry Genetics, Quest Diagnostics , and LabCorp, all of which have greater resources at their disposal than Gene by Gene, in our opinion.